Merck + Co., Inc.

John G Menke

John W Hess

David L Linemeyer

Joseph A Borkowski

Kathleen K Bierilo

Douglas J MacNeil

Roy G Smith

Margaret A Cascieri

Euan MacIntyre

DNAs encoding bradykinin B,receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind desArg,kallidin and other B,-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Bradykinin B1 receptor antibodies

DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Purified bradykinin B.sub.1 receptor

The combination of a metabolic rate modifying agent (e.g., a .beta..sub.3 adrenergic receptor agonist) and a feeding behavior modifying agent (e.g., a NPY5 antagonist) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients. Methods of treating obesity and diabetes are also described.

Combination therapy for the treatment of diabetes and obesity

DNA encoding bradykinin B1 receptor

Growing community of inventors

Morganville, NJ, United States of America

John G Menke